Biogix is a science-driven company that develops, tests, manufactures, and distributes innovative products based on the unique platform of natural metabolites.

Since its inception in 2006, the year when Biogix acquired the rights to its flagship product Amberen, the company has been supporting the clinical and scientific research and development of its formulation.

The impressive history of science behind Amberen goes all the way back to the 1970s, when a team of researchers led by Dr. Vladimir Dilman reversed menopause in aging rats by restoring their hypothalamic function using an early prototype of what is now Amberen.

Launched on the United States market in 2007, Amberen continues to improve the quality of life of many women going through menopause by restoring their hormonal balance and helping to relieve multiple symptoms.